The Latest Cardiac and Vascular News
Medtronic plc, a global leader in healthcare technology, today announced its Penditure™ Left Atrial Appendage (LAA) Exclusion System has officially received CE Mark approval and will be launched in Europe at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark. The Penditure device recently […]
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today GALWAY, Ireland, Sept. 15, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in…
The upcoming U.S. launch of the small-diameter OmniaSecure defibrillation lead will introduce the first FDA-approved lead for both adults and adolescent pediatric patients Cardiac Rhythm Management At the 2025 European Society of Cardiology (ESC) Congress in Madrid, researchers presented three new datasets reinforcing the safety and performance of the OmniaSecure™ […]
Japan is now the 77th country to receive regulatory approval for the Symplicity Spyral Renal Denervation System Medtronic, a global leader in healthcare technology, today announced it received approval in Japan from the Pharmaceuticals and Medical Devices Agency (PMDA) for its Symplicity Spyral™ renal denervation (RDN) system, also known as […]
Medtronic plc, a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the expanded Redo-TAVR indication of the Evolut™ transcatheter aortic valve replacement (TAVR) system. This approval allows for the implantation of a new Evolut transcatheter aortic valve (TAV) inside any failed […]
Medtronic advances pipeline with update on multi-organ denervation study and additional data recently presented at EuroPCR 2025 Medtronic, a global leader in healthcare technology, today announced that it has treated the first patient in its SPYRAL GEMINI Pilot program (including ‘OFF MED’ and ‘ON MED’ studies).* The first patient […]
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results…
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent…
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve…
CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to primarily enroll women using the two most widely used global TAVR devices GALWAY, Ireland and WASHINGTON, March 9, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare…
